A new study in Japan found that in the pathogenesis of psoriasis, a signaling molecule in skin cells plays a key role, and on this basis, it is expected to develop new therapeutic methods.

    Psoriasis is a skin disease associated with immune abnormalities, manifested by erythema, silver shavings and itching on the skin. According to the researchers, psoriasis patients account for about 3% of the global population. In recent years, injection antibody therapy has a good effect, but the cost of treatment is high, and some patients may have antibody failure.

    In a new issue of Epithelial TRAF6 drives IL-17–mediated psoriatic inflammation on the Journal of JCI Insight, the researchers reported that a signal molecule "TRAF6" in skin cells plays a key role in the pathogenesis of psoriasis.

    In mice, mice lacking this signaling molecule do not develop psoriasis. Even when these mice were injected with immunomodulatory factors, immune abnormalities that could have caused psoriasis were induced, and psoriasis was still suppressed.

    Researchers therefore believe that new treatments for psoriasis can be developed for this signaling molecule to address the challenges of previous related therapies.

    EIAAB SCIENCE INC, WUHAN has developed several related kits such as E8869h, E8869m, E0063h and E2103h etc. Welcome scientific research workers to choose and purchase.